Machine learning algorithms integrating positron emission tomography/computed tomography features to predict pathological complete response after neoadjuvant chemoimmunotherapy in lung cancer.

IF 3 2区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Zhenxin Sheng, Shuyu Ji, Yancheng Chen, Zirong Mi, Huansha Yu, Lele Zhang, Shiyue Wan, Nan Song, Ziyun Shen, Peng Zhang
{"title":"Machine learning algorithms integrating positron emission tomography/computed tomography features to predict pathological complete response after neoadjuvant chemoimmunotherapy in lung cancer.","authors":"Zhenxin Sheng, Shuyu Ji, Yancheng Chen, Zirong Mi, Huansha Yu, Lele Zhang, Shiyue Wan, Nan Song, Ziyun Shen, Peng Zhang","doi":"10.1093/ejcts/ezaf132","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Reliable methods for predicting pathological complete response (pCR) in non-small cell lung cancer (NSCLC) patients undergoing neoadjuvant chemoimmunotherapy are still under exploration. Although Fluorine-18 fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG PET/CT) features reflect tumour response, their utility in predicting pCR remains controversial.</p><p><strong>Methods: </strong>This retrospective analysis included NSCLC patients who received neoadjuvant chemoimmunotherapy followed by 18F-FDG PET/CT imaging at Shanghai Pulmonary Hospital from October 2019 to August 2024. Eligible patients were randomly divided into training and validation cohort at a 7:3 ratio. Relevant 18F-FDG PET/CT features were evaluated as individual predictors and incorporated into 5 machine learning (ML) models. Model performance was assessed using the area under the receiver operating characteristic curve (AUC), and Shapley additive explanation was applied for model interpretation.</p><p><strong>Results: </strong>A total of 205 patients were included, with 91 (44.4%) achieving pCR. Post-treatment tumour maximum standardized uptake value (SUVmax) demonstrated the highest predictive performance among individual predictors, achieving an AUC of 0.72 (95% CI 0.65-0.79), while ΔT SUVmax achieved an AUC of 0.65 (95% CI 0.53-0.77). The Light Gradient Boosting Machine algorithm outperformed other models and individual predictors, achieving an average AUC of 0.87 (95% CI 0.78-0.97) in training cohort and 0.83 (95% CI 0.72-0.94) in validation cohort. Shapley additive explanation analysis identified post-treatment tumour SUVmax and post-treatment nodal volume as key contributors.</p><p><strong>Conclusions: </strong>This ML models offer a non-invasive and effective approach for predicting pCR after neoadjuvant chemoimmunotherapy in NSCLC.</p>","PeriodicalId":11938,"journal":{"name":"European Journal of Cardio-Thoracic Surgery","volume":"67 5","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cardio-Thoracic Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ejcts/ezaf132","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Reliable methods for predicting pathological complete response (pCR) in non-small cell lung cancer (NSCLC) patients undergoing neoadjuvant chemoimmunotherapy are still under exploration. Although Fluorine-18 fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG PET/CT) features reflect tumour response, their utility in predicting pCR remains controversial.

Methods: This retrospective analysis included NSCLC patients who received neoadjuvant chemoimmunotherapy followed by 18F-FDG PET/CT imaging at Shanghai Pulmonary Hospital from October 2019 to August 2024. Eligible patients were randomly divided into training and validation cohort at a 7:3 ratio. Relevant 18F-FDG PET/CT features were evaluated as individual predictors and incorporated into 5 machine learning (ML) models. Model performance was assessed using the area under the receiver operating characteristic curve (AUC), and Shapley additive explanation was applied for model interpretation.

Results: A total of 205 patients were included, with 91 (44.4%) achieving pCR. Post-treatment tumour maximum standardized uptake value (SUVmax) demonstrated the highest predictive performance among individual predictors, achieving an AUC of 0.72 (95% CI 0.65-0.79), while ΔT SUVmax achieved an AUC of 0.65 (95% CI 0.53-0.77). The Light Gradient Boosting Machine algorithm outperformed other models and individual predictors, achieving an average AUC of 0.87 (95% CI 0.78-0.97) in training cohort and 0.83 (95% CI 0.72-0.94) in validation cohort. Shapley additive explanation analysis identified post-treatment tumour SUVmax and post-treatment nodal volume as key contributors.

Conclusions: This ML models offer a non-invasive and effective approach for predicting pCR after neoadjuvant chemoimmunotherapy in NSCLC.

结合正电子发射断层扫描/计算机断层扫描特征的机器学习算法预测肺癌新辅助化疗免疫治疗后的病理完全缓解。
目的:预测接受新辅助化疗免疫治疗的非小细胞肺癌(NSCLC)患者病理完全缓解(pCR)的可靠方法仍在探索中。尽管氟-18氟脱氧葡萄糖-正电子发射断层扫描/计算机断层扫描(18F-FDG PET/CT)特征反映了肿瘤反应,但它们在预测pCR中的应用仍存在争议。方法:回顾性分析2019年10月至2024年8月在上海肺科医院接受新辅助化疗免疫治疗并进行18F-FDG PET/CT成像的非小细胞肺癌患者。符合条件的患者按7:3的比例随机分为训练组和验证组。相关的18F-FDG PET/CT特征作为单独的预测因子进行评估,并纳入5个机器学习(ML)模型。采用受试者工作特征曲线下面积(AUC)评价模型性能,采用Shapley加性解释进行模型解释。结果:共纳入205例患者,其中91例(44.4%)实现pCR。治疗后肿瘤最大标准化摄取值(SUVmax)在个体预测因子中表现出最高的预测性能,达到0.72 (95% CI 0.65-0.79),而ΔT SUVmax达到0.65 (95% CI 0.53-0.77)。光梯度增强机算法优于其他模型和单个预测因子,在训练队列中平均AUC为0.87 (95% CI 0.78-0.97),在验证队列中平均AUC为0.83 (95% CI 0.72-0.94)。Shapley加性解释分析确定治疗后肿瘤SUVmax和治疗后淋巴结体积是关键因素。结论:该ML模型为非小细胞肺癌新辅助化疗免疫治疗后pCR预测提供了一种无创、有效的方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.60
自引率
11.80%
发文量
564
审稿时长
2 months
期刊介绍: The primary aim of the European Journal of Cardio-Thoracic Surgery is to provide a medium for the publication of high-quality original scientific reports documenting progress in cardiac and thoracic surgery. The journal publishes reports of significant clinical and experimental advances related to surgery of the heart, the great vessels and the chest. The European Journal of Cardio-Thoracic Surgery is an international journal and accepts submissions from all regions. The journal is supported by a number of leading European societies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信